Hybrid interferons, their use as pharmaceutical compositions and as intermediate products for the preparation of antibodies and the use thereof and processes for preparing them

US4917887A · kind A · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Rudolf Hauptmann · Ebreichsdorf, AT
• Peter Swetly · Wien, AT
• Peter Meindl · Wien, AT
• Gunther Adolf · Wien, AT
• Edgar Falkner · Wien, AT
• Gerhard Bodo · Wien, AT
• Ingrid Maurer-Fogy · Wien, AT

Key dates

• Filing date: Mar 9, 1987
• Grant date: Apr 17, 1990
• Expiry date: Mar 9, 2007

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them, PA1 new monoclonal antibodies and their use in purifying .alpha. and omega-interferons, the hybrid cell lines which secrete them and processes for preparing them, PA1 a new process for purifying .alpha. and omega-interferons by means of a new antibody affinity column containing the above-mentioned new monoclonal antibodies, and processes for the preparation thereof, PA1 new hybrid plasmids for improving the expression of omega-interferons and new intermediate plasmids for preparing the new plasmids and processes for the preparation thereof.